Enbrel Effective In Arthritis, Says Study
As Immunex' Phase III trial of its novel treatment for rheumatoidarthritis Enbrel (tumor necrosis factor receptor) nears completion, the drug has been shown to improve the symptoms of rheumatoid arthritis in a multidose Phase II study published in the New England Journal of Medicine (July 17).
In the study, 180 patients with refractory rheumatoid arthritis were given either subcutaneous injections of placebo or one of three doses of Enbrel (0.25mg, 2mg, or 16mg/m2) twice weekly for three months.
At three months, 75% of the patients in the group assigned to the most effective dose (16mg/m2) had improvement of 20% or more in symptoms, measured by changes in composite symptoms of arthritis defined according to American College of Rheumatology criteria. This compared with 14% in the placebo group (p<0.001).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze